| Authors: |
Shulman DS; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA., Chen S; Nationwide Children's Hospital, Columbus, OH, USA., Hall D; Children's Oncology Group, Monrovia, CA, USA., Nag A; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Thorner AR; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA, USA., Lessnick SL; Nationwide Children's Hospital, Columbus, OH, USA., Stegmaier K; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA., Janeway KA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA., DuBois SG; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA., Krailo MD; Children's Oncology Group, Monrovia, CA, USA.; Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA., Barkauskas DA; Children's Oncology Group, Monrovia, CA, USA.; Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA., Church AJ; Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Crompton BD; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA. briand_crompton@dfci.harvard.edu.; Broad Institute, Cambridge, MA, USA. briand_crompton@dfci.harvard.edu. |
